Clinicopathological Characteristics and Outcomes of Chinese Patients with Scanty Immune Deposits Lupus Nephritis: A Large Cohort Study from a Single Center
Table 5
Comparison of treatment between patients with scanty immune deposits and immune complex deposits lupus nephritis.
Scanty immune deposits
Immune complex deposits
value
Number of patients (%)
40
276
Treatment
P
40 (100)
276 (100)
1
CYC
23 (57.50)
156 (56.52)
0.907
AZA
4 (10.00)
21 (7.60)
0.833
MMF
3 (7.50)
17 (6.15)
1
LEF
8 (20.00)
31 (11.23)
0.187
Treatment response
CR
8 (20.00)
78 (28.26)
0.560
PR
18 (45.00)
145 (52.54)
0.373
TF
14 (35)
53 (19.20)
0.001
Duration of followup (months)
38, 6–78
48, 8.5–84
0.952
Relapse rate
4 (4/26, 15.38%, 3 with nephritic relapse and 1 with proteinuric relapse)
28 (28/223, 12.56%, 20 with nephritic relapse and 8 with proteinuric relapse)
0.922
Note: P: oral prednisone; CYC: cyclophosphamide; AZA: azathioprine; MMF: mycophenolate mofetil; LEF: leflunomide; CR: complete remission; PR: partial remission; TF: treatment failure. , italic values refer to the significant value between the two groups.
